
Biofreeze® vs. a Placebo on Knee Osteoarthritis Walking Gait Characteristics and Pain
Knee OsteoarthritisThe purpose of this study is to determine the effect of Biofreeze® versus a placebo on walking gait characteristics and pain during walking in individuals with bilateral knee osteoarthritis (OA).

Lipogems Prospective Study
Knee OsteoarthritisThe purpose of this study is to study the clinical outcomes and effects of the injection of fat-derived stem cells (the scientific name being "adipose derived autologous stem cell transplantation (ADAT)") as an addition to knee arthroscopy in the treatment of knee swelling and pain associated with mild to moderate knee osteoarthritis. Management of this condition remains a pervasive problem within orthopaedics. Lipogems is a Food and Drug Administration (FDA) approved technique. Lipogems is the name of the technology used to obtain stem cells from fat that will be aspirated/removed by suction from the abdomen. Fat will be processed to obtain stem cells which will then be injected into the knee after the physician completes knee arthroscopy. The study that we are asking patients to enroll in is important because it will attempt to answer the question about whether fat-derived stem cells added to knee arthroscopy is better, worse or no different than knee arthroscopy alone. Currently, without this study, we do not have an answer to this question.

Prospective Study for the Evaluation of the Cementless Anatomic Femoral Stem Minimax -Launay
Primary OsteoarthritisSecondary Osteoarthritis6 moreThis is a post-marketing surveillance on MiniMAX Stem

A Multicentre Trial to Compare Two Articulating Bearing Surfaces as Used in Cementless Primary Hip...
OsteoarthritisThe aim of this study is to demonstrate the non-inferiority of the ceramic-on-metal articulation using large diameter bearings (38mm to 60mm) compared to the metal on metal articulation using the same cup in regards to the composite clinical success (CCS) rate at 2 years postoperatively (delta = 10% minimum clinically significant difference in rates).

Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis...
Knee OsteoarthritisHypothesis: Viscosupplementation when combined with an off-loading knee brace is more effective in treating the symptoms of knee OA then treating with viscosupplementation alone

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients...
OsteoarthritisOsteoarthritis6 moreThe purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe knee or hip pain in patients with a diagnosis of osteoarthritis.

Ultrasound (US)-Guided Versus Sham Ultrasound Corticosteroid (CS) Knee Injections
OsteoarthritisTo determine if ultrasound-guided knee steroid injections are more effective than sham ultrasound knee steroid injections for the treatment of osteoarthritis.

Tanezumab and Nerve Function In Arthritis Patients
OsteoarthritisTanezumab reduces pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves.

Modulation of the Surgical Inflammatory Response by Etoricoxib
PainOsteoarthritis2 moreThe purpose of this study is to test the hypothesis that orally administered etoricoxib (COX-2) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients and thus reduces pain and suffering.

The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis
Symptomatic Hip OsteoarthritisTo demonstrate the difference in terms of symptomatic efficacy between ADANT® sodium hyaluronate and placebo following an intra-articular injection in patients with symptomatic osteoarthritis of the hip. Each patient will receive an injection of sodium hyaluronate or placebo in the symptomatic hip and will be followed up for three months. At the third month, if the score for overall pain is still > 40 mm on the VAS, a second injection of ADANT® can be given irrespective of which treatment was received previously. The patient will be followed up for a further 3 months in an open-label fashion (monthly visits).